| |
| What CATIE found: results from the schizophrenia trial |
| Swartz M S, Stroup T S, McEvoy J P, Davis S M, Rosenheck R A, Keefe R S, Hsiao J K, Lieberman J A |
|
|
| |
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Swartz M S, Stroup T S, McEvoy J P, Davis S M, Rosenheck R A, Keefe R S, Hsiao J K, Lieberman J A. What CATIE found: results from the schizophrenia trial. Psychiatric Services 2008; 59(5): 500-506 Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Aged; Antipsychotic Agents /adverse effects /economics /therapeutic use; Benzodiazepines /adverse effects /economics /therapeutic use; Cost-Benefit Analysis; Dibenzothiazepines /adverse effects /economics /therapeutic use; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced /epidemiology /etiology; Female; Humans; Male; Middle Aged; Perphenazine /adverse effects /economics /therapeutic use; Piperazines /adverse effects /economics /therapeutic use; Psychology; Quetiapine Fumarate; Risperidone /adverse effects /economics /therapeutic use; Schizophrenia /drug therapy /economics; Thiazoles /adverse effects /economics /therapeutic use AccessionNumber 22008102443 Date bibliographic record published 22/04/2009 |
| |
|
|
